BRISTOL-MYERS SQUIBB GLUCOPHAGE 1996 SALES TARGET IS $200 MIL., COMPANY TELLS ANALYSTS; COST-CUTTING MOVES ARE PROJECTED TO SAVE $1.1 BIL. TO $1.5 BIL. BY 1998

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".